Parasomnia induced by lemborexant: a case report.
Journal
International clinical psychopharmacology
ISSN: 1473-5857
Titre abrégé: Int Clin Psychopharmacol
Pays: England
ID NLM: 8609061
Informations de publication
Date de publication:
11 Mar 2024
11 Mar 2024
Historique:
medline:
11
3
2024
pubmed:
11
3
2024
entrez:
11
3
2024
Statut:
aheadofprint
Résumé
Lemborexant, an orexin receptor antagonist, is effective not only for sleep disorders but also for preventing and treating delirium. To date, no complex sleep-related behaviors due to lemborexant have been reported. Herein, we present the case of a 69-year-old male patient who was hospitalized for oral floor and tongue cancer and developed delirium after surgery; however, upon lemborexant dosage increase, used to treat insomnia, he developed abnormal nocturnal behavior. This symptom rapidly improved when lemborexant was discontinued. Distinguishing parasomnia from delirium is important because the treatment of these two conditions differs. Although rapid eye movement sleep behavior or sleepwalking was the cause of this parasomnia, a definitive diagnosis could not be established. If qualitatively distinct abnormal behavior is observed compared to delirium after increasing lemborexant dosage, the possibility of parasomnia should be considered.
Identifiants
pubmed: 38465918
doi: 10.1097/YIC.0000000000000546
pii: 00004850-990000000-00132
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Références
Anon (2020/2023 Efficacy and Safety of Suvorexant (MK-4305) for Reducing Incidence of Delirium in Japanese Participants at High Risk of Delirium (MK-4305-085). https://clinicaltrials.gov/study/NCT04571944. [Accessed 16 January 2024].
American Academy of Sleep Medicine AAoS (2014). International classification of sleep disorders (3rd ed). Darien, IL: American Academy of Sleep Medicine.
American Psychiatric Association AP (2013). American Psychiatric Association. Diagnostic and statistical manual of mental disorders (5th ed). Washintgton, DC: American Psychiatric Association Publishing.
Arnulf I (2018). Sleepwalking. Curr Biol 28:R1288–R1289.
Bergeron N, Dubois MJ, Dumont M, Dial S, Skrobik Y (2001). Intensive care delirium screening checklist: evaluation of a new screening tool. Intensive Care Med 27:859–864.
Beuckmann CT, Suzuki M, Ueno T, Nagaoka K, Arai T, Higashiyama H (2017). In Vitro and In Silico Characterization of Lemborexant (E2006), a Novel Dual Orexin Receptor Antagonist. J Pharmacol Exp Ther 362:287–295.
Citrome L, Juday T, Frech F, Atkins N Jr (2021). Lemborexant for the treatment of insomnia: direct and indirect comparisons with other hypnotics using number needed to treat, number needed to harm, and likelihood to be helped or harmed. J Clin Psychiatry 82:20m13795.
Folstein MF, Folstein SE, McHugh PR (1975). ‘Mini-mental state’. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198.
Horikoshi S, Miura I, Suzuki Y, Kobayashi Y, Hirata Y, Goto M, et al. (2023). Switching to lemborexant for the management of insomnia in mental disorders: the SLIM study. J Clin Sleep Med 19:1753–1758.
Hu MT (2020). REM sleep behavior disorder (RBD). Neurobiol Dis 143:104996.
Matsuoka A, Tobita S, Sogawa R, Shinada K, Murakawa-Hirachi T, Shimanoe C, et al. (2022). Evaluation of suvorexant and lemborexant for the prevention of delirium in adult critically ill patients at an advanced critical care center: a single-center, retrospective, observational study. J Clin Psychiatry 84:22m–14471.
Matsuoka A, Sogawa R, Murakawa-Hirachi T, Mizoguchi Y, Monji A, Shimanoe C, et al. (2023). Evaluation of the delirium preventive effect of dual orexin receptor antagonist (DORA) in critically ill adult patients requiring ventilation with tracheal intubation at an advanced emergency center: a single-center, retrospective, observational study. Gen Hosp Psychiatry 83:123–129.
Moline M, Zammit G, Cheng JY, Perdomo C, Kumar D, Mayleben D (2021). Comparison of the effect of lemborexant with placebo and zolpidem tartrate extended release on sleep architecture in older adults with insomnia disorder. J Clin Sleep Med 17:1167–1174.
Nakamura T, Yoshizawa T, Toya R, Terasawa M, Takahashi K, Kitazawa K, et al. (2023). Orexin receptor antagonists versus antipsychotics for the management of delirium in intensive care unit patients with cardiovascular disease: A retrospective observational study. Gen Hosp Psychiatry 84:96–101.
Ogura T, Ueno S, Okuda A, Nishioka N, Miyano A, Yamamoto Y, et al. (2022). Can lemborexant for insomnia prevent delirium in high-risk patients with pancreato-biliary disease after endoscopic procedures under deep sedation? J Clin Med 12:297.
Okuda S, Qureshi ZP, Yanagida Y, Ito C, Homma Y, Tokita S (2023). Hypnotic prescription trends and patterns for the treatment of insomnia in Japan: analysis of a nationwide Japanese claims database. BMC Psychiatry 23:278.
Rosenberg R, Murphy P, Zammit G, Mayleben D, Kumar D, Dhadda S, et al. (2019). Comparison of lemborexant with placebo and zolpidem tartrate extended release for the treatment of older adults with insomnia disorder: a phase 3 randomized clinical trial. JAMA Netw Open 2:e1918254.
Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL (2017). Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an american academy of sleep medicine clinical practice guideline. J Clin Sleep Med 13:307–349.
Shibata S, Oda Y, Ohki N, Ikemizu Y, Hayatsu R, Hirose Y, et al. (2022). Narcolepsy-like symptoms triggered by lemborexant in the context of hyperactive delirium in a patient with bipolar depression: a case report. J Clin Sleep Med 18:1459–1462.
Sugishita M, Koshizuka Y, Sudou S, Sugishita K, Hemmi I, Karasawa H, et al. (2018). The validity and reliability of the Japanese version of the mini-mental state examination (MMSE-J) with the original procedure of the attention and calculation task (2001). J. Cogn. Neurosci 20:91–110.
Tachibana M, Kanahara N, Oda Y, Hasegawa T, Kimura A, Iyo M (2023). A retrospective clinical practice study comparing the usefulness of dual-orexin receptor antagonists and a melatonin receptor agonist in patients switching from long-term benzodiazepine receptor agonists. J Clin Sleep Med 8. [Epub ahead of print].
Takeshima M, Yoshizawa K, Enomoto M, Ogasawara M, Kudo M, Itoh Y, et al. (2023). Effects of Japanese policies and novel hypnotics on long-term prescriptions of hypnotics. Psychiatry Clin Neurosci 77:264–272.
Terada T, Hirayama T, Sadahiro R, Wada S, Nakahara R, Matsuoka H (2022). Pilot study of lemborexant for insomnia in cancer patients with delirium. J Palliat Med 25:797–801.
Xue T, Wu X, Chen S, Yang Y, Yan Z, Song Z, et al. (2022). The efficacy and safety of dual orexin receptor antagonists in primary insomnia: a systematic review and network meta-analysis. Sleep Med Rev 61:101573.